JP2023549706A5 - - Google Patents
Info
- Publication number
- JP2023549706A5 JP2023549706A5 JP2023526269A JP2023526269A JP2023549706A5 JP 2023549706 A5 JP2023549706 A5 JP 2023549706A5 JP 2023526269 A JP2023526269 A JP 2023526269A JP 2023526269 A JP2023526269 A JP 2023526269A JP 2023549706 A5 JP2023549706 A5 JP 2023549706A5
- Authority
- JP
- Japan
- Prior art keywords
- nkd2
- kidney disease
- chronic kidney
- antigen
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102020128677.5A DE102020128677A1 (de) | 2020-10-30 | 2020-10-30 | Ein neues Target zur Behandlung der Nierenfibrose |
| DE102020128677.5 | 2020-10-30 | ||
| PCT/EP2021/080068 WO2022090434A1 (de) | 2020-10-30 | 2021-10-28 | Nkd2 als target zur behandlung von nierenfibrose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549706A JP2023549706A (ja) | 2023-11-29 |
| JP2023549706A5 true JP2023549706A5 (https=) | 2026-03-25 |
Family
ID=78528918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526269A Pending JP2023549706A (ja) | 2020-10-30 | 2021-10-28 | 腎線維症の治療標的としてのＮｋｄ２ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240391985A1 (https=) |
| EP (1) | EP4237078A1 (https=) |
| JP (1) | JP2023549706A (https=) |
| KR (1) | KR20230098243A (https=) |
| CN (1) | CN116783210A (https=) |
| CA (1) | CA3195914A1 (https=) |
| DE (1) | DE102020128677A1 (https=) |
| WO (1) | WO2022090434A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO2000049034A1 (en) | 1999-02-17 | 2000-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Naked cuticle genes and their uses |
| EP1432724A4 (en) * | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
| DE202007018529U1 (de) | 2007-07-07 | 2008-12-04 | Chamalow S.A. | Implantierbarer Funkfrequenzdefibrillator R.F. |
| US9970935B2 (en) * | 2014-02-06 | 2018-05-15 | The Brigham And Women's Hospital, Inc. | Uses of GLI1 in detecting tissue fibrosis |
-
2020
- 2020-10-30 DE DE102020128677.5A patent/DE102020128677A1/de active Pending
-
2021
- 2021-10-28 EP EP21802638.3A patent/EP4237078A1/de active Pending
- 2021-10-28 KR KR1020237017649A patent/KR20230098243A/ko active Pending
- 2021-10-28 CN CN202180087798.6A patent/CN116783210A/zh active Pending
- 2021-10-28 WO PCT/EP2021/080068 patent/WO2022090434A1/de not_active Ceased
- 2021-10-28 US US18/249,694 patent/US20240391985A1/en active Pending
- 2021-10-28 CA CA3195914A patent/CA3195914A1/en active Pending
- 2021-10-28 JP JP2023526269A patent/JP2023549706A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12152059B2 (en) | Method of treating nash using a long-acting mutant human fibroblast growth factor | |
| JP7046003B2 (ja) | 高ｍ６ｐ組換えタンパク質の選択方法 | |
| US20240325417A1 (en) | Combination therapy for treatment of liver diseases | |
| CN105753963B (zh) | 高活性艾塞那肽类似物及其医药应用 | |
| CA3101274A1 (en) | Use of neutrophil elastase inhibitors in liver disease | |
| CN112166111A (zh) | 治疗纤维化疾病的方法 | |
| CN110064045B (zh) | 微肽cip2a-bp在治疗癌症中的应用 | |
| JP2011506436A (ja) | 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| JP6055845B2 (ja) | ペプチドおよびその使用 | |
| JP2023507364A (ja) | インテグリン阻害剤を使用する肝疾患の治療の組み合わせ | |
| JP2025508852A (ja) | 環状ホスホネート組成物およびその調製方法 | |
| JP2023549706A5 (https=) | ||
| TWI845975B (zh) | 用於治療肝臟疾病的聯合治療 | |
| KR20220051418A (ko) | 근위축성 측삭 경화증 치료제 | |
| CN104548066A (zh) | 一种具有降血糖作用的新型肽的新用途 | |
| CN119950745B (zh) | 一种药物组合物及其在制备抗肿瘤药物中的应用 | |
| Chen et al. | Dual metabolic-inflammation modulation in MicroRNA@ neutrophil-derived microvesicles achieve robust osteoarthritis therapy | |
| EA050073B1 (ru) | Комбинированная терапия для лечения заболеваний печени | |
| JP2023064002A (ja) | Ｍａｒｋ４阻害活性を有する新規ペプチド | |
| JP7317343B2 (ja) | 乳がんの予防又は治療剤及び乳がん細胞の増殖抑制剤 | |
| HK40104848A (zh) | 肝病治疗的组合疗法 | |
| KR20250127153A (ko) | 약물 조합 및 이의 용도 | |
| CN121695136A (zh) | 焦脱镁叶绿酸-alpha在制备治疗慢性胰腺炎的药物中的应用 | |
| WO2025161058A1 (zh) | PPARα/δ双重激动剂在治疗多囊肾疾病中的应用 | |
| CN121130057A (zh) | 黑素细胞刺激素α-MSH在治疗肝癌中的应用 |